Benzotriazine oxides as drugs targeting
Benzotriazine doxides are disclosed as drugs targeting mycobacterium tuberculosis , including novel compounds of formula I:
1. A compound of having a structure selected from the following table:
or a pharmaceutically acceptable salt or stereoisomer thereof.
2. The compound of claim 1 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
3. The compound of claim 1 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
4. A compound having a structure selected from the following table:
SRI-012495
SRI-012530
SRI-012562
SRI-012563
SRI-012564
SRI-012565
SRI-012566
SRI-012567
SRI-012568
or a pharmaceutically acceptable salt or stereoisomer thereof.
5. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
6. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
7. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
8. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
9. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
10. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
11. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
12. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
13. The compound of claim 4 that is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
14. A pharmaceutical composition or kit comprising a compound of claim 1 and a second, different anti- mycobacterium tuberculosis (Mtb) drug.
15. A pharmaceutical composition or kit comprising a compound of claim 4 and a second, different anti- mycobacterium tuberculosis (Mtb) drug.
16. A method of making a compound of claim 1 according to the following scheme:
(a) HOFACN, DCM; b) HNR 2 R 3 , Et 3 N, DCM; wherein X is R 1 , W is N, A is R 3 and B is R 2 .
17. A method of making a compound of claim 4 according to the following scheme:
(a) HOFACN, DCM; b) HNR 2 R 3 , Et 3 N, DCM; wherein X is R 1 , W is N, A is R 3 and B is R 2 .
18. A method of treating a mycobacterium tuberculosis (Mtb) infection, comprising: contacting a person in need thereof with an effective amount of compound of claim 1 .
19. A method of treating a mycobacterium tuberculosis (Mtb) infection, comprising: contacting a person in need thereof with an effective amount of compound of claim 4 .